




PCT/GB 2004 / 0 0 3 5 1 6



INVESTOR IN PEOPLE

27 AUG 2004

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Stephen Hordley

Dated

2 August 2004

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY



The
Patent
Office

15AUG03 E83041-2 001030
P01/7700 0.00-0319126.9

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your Reference	RMT/PB60300P	0319126.9
2. Patent application number (The Patent office will fill in this part)	14 AUG 2003	
3. Full name, address and postcode of the or of each applicant (underline all surnames)	SMITHKLINE BEECHAM CORPORATION ONE FRANKLIN PLAZA P.O. BOX 7929 PHILADELPHIA PENNSYLVANIA 19101 UNITED STATES OF AMERICA	
Patents ADP number (if you know it)	5949417004	
If the applicant is a corporate body, give the country/state of its corporation	UNITED STATES OF AMERICA	
4 Title of the invention	CHEMICAL COMPOUNDS	
5 Name of your agent (if you know one)	RACHEL M THORNLEY	
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY (CN9 25.1) 980 GREAT WEST ROAD BRENTFORD, MIDDLESEX TW8 9GS, GB	
Patents ADP number (if you know it)	8072555004	
6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)
		Date of Filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body.	YES	

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form -

Description 25

Claim(s) 8

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patent Form 9/77*)

Request for substantive examination (*Patent Form 10/77*)

Any other documents (*please specify*)

11. I/We request the grant of a patent on the basis of this application

Signature RACHEL M THORNLEY
AGENT FOR THE APPLICANTS

14 August, 2003

12. Name and daytime telephone number of person to contact in the United Kingdom
JACKIE ROBINSON
020 8047 4458

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) Notes

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form

If you have answered "Yes" Patents Form 7/77 will need to be filed.

d) Once you have filled in the form you must remember to sign and date it.

e) For details of the fee and ways to pay please contact the Patent Office.

CHEMICAL COMPOUNDS

The present invention relates to therapeutically active compounds which are anthranilic acid derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

Dyslipidaemia is a general term used to describe individuals with aberrant lipoprotein profiles. Clinically, the main classes of compounds used for the treatment of patients with dyslipidaemia, and therefore at risk of cardiovascular disease are the statins, fibrates, bile-acid binding resins and nicotinic acid. Nicotinic acid (Niacin, a B vitamin) has been used clinically for over 40 years in patients with various forms of dyslipidaemia. The primary mode of action of nicotinic acid is via inhibition of hormone-sensitive triglyceride lipase (HSL), which results in a lowering of plasma non-esterified fatty acids (NEFA) which in turn alters hepatic fat metabolism to reduce the output of LDL and VLDL (low and very low density lipoprotein). Reduced VLDL levels are thought to lower cholesterol ester transfer protein (CETP) activity to result in increased HDL (high density lipoprotein) levels which may be the cause of the observed cardiovascular benefits. Thus, nicotinic acid produces a very desirable alteration in lipoprotein profiles; reducing levels of VLDL and LDL whilst increasing HDL. Nicotinic acid has also been demonstrated to have disease modifying benefits, reducing the progression and increasing the regression of atherosclerotic lesions and reducing the number of cardiovascular events in several trials.

The observed inhibition of HSL by nicotinic acid treatment is mediated by a decrease in cellular cyclic adenosine monophosphate (cAMP) caused by the G-protein-mediated inhibition of adenylyl cyclase. Recently, the G-protein coupled receptors HM74 and HM74A have been identified as receptors for nicotinic acid (PCT patent application WO02/84298; Wise et. al. J Biol Chem. 2003 278 (11) 9869-9874). Two other papers support this discovery, (Tunaru et. al. Nature Medicine 2003 (3) 352-255 and Soga et. al. Biochem Biophys Res Commun. 2003 303 (1) 364-369), however the nomenclature differs slightly. In the Tunaru paper what they term human HM74 is in fact HM74A and in the Soga paper HM74b is identical to HM74A. Cells transfected to express HM74A and/or HM74 gain the ability to elicit G_i G-protein mediated responses following exposure to nicotinic acid. In mice lacking the homologue of HM74A (m-PUMA-G) nicotinic acid fails to reduce plasma NEFA levels.

Certain anthranilic acid derivatives have been synthesised and disclosed in the prior art. For example, US patent No. 5,075,313 and Yu, Melvin J. *et. al.* J. Med. Chem. 1992, vol.

35, 2534-2542 both relate to 3-aryl-4(3H)quinazolinone CCK antagonists useful in treating CNS and gastrointestinal disorders and discloses certain anthranilic acid derivatives as intermediates in their synthesis.

- 5 We now present a group of anthranilic acid derivatives which are selective agonists of the nicotinic acid receptor HM74A and are thus of benefit in the treatment, prophylaxis and suppression of diseases where under-activation of this receptor either contributes to the disease or where activation of the receptor will be beneficial.

10 Summary of the Invention

The present invention provides therapeutically active anthranilic acid derivatives and the use of these derivatives in therapy, particularly in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, in particular diseases of lipid metabolism including dyslipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia. As such, the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease, and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity. the compounds may also be of use in the treatment of inflammatory diseases or conditions, as set out further below.


25

Intermediates, formulations, methods and processes described herein form further aspects of the invention.

Detailed Description of the Invention

30

According to one aspect of this invention, we provide a compound of Formula (I)



and salts, solvates and physiologically functional derivatives thereof, wherein:

R¹ represents hydrogen, halogen or C₁-C₃alkyl;

R² represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; and $-O-$;

n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

R³ represents hydrogen or C₁-C₄alkyl;

with the proviso that when R¹ is H, Z is $-(CH_2)_n-$ and n = 2 or 3, R² is other than indol-3-yl.

The compounds are of use in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, in particular diseases of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia. As such, the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.

In preferred embodiments, R¹ represents hydrogen, fluorine or methyl, with hydrogen being particularly preferred.

In preferred embodiments, Z represents $-(CH_2)_n-$ or $-CH=CH-(CH_2)_m-$.

In certain preferred embodiments n represents 2 or 3, most desirably 2.

Desirably, m represents 0 or 1, most preferably 0.

In preferred embodiments, p represents 1.

R^3 preferably represents hydrogen or methyl.


5

R^2 may represent a biaryl, hetero-biaryl, fused aryl-cycloalkyl, fused heteroaryl-cycloalkyl, fused aryl-heterocycle or fused heteroaryl-heterocyclic ring system, as herein defined. Where R^2 includes heteroatoms, preferably 1 to 3 heteroatoms are present. The R^2 ring system may be joined to the Z linker unit via either a ring carbon atom or via

10

Where the R^2 unit is a 10-member ring system, this is preferably naphthyl or has either 1 or 2 heteroatoms. Where 2 heteroatoms are present, these are preferably both in the same ring of the fused system. Preferably the one or two heteroatoms in a 10-member ring system are nitrogen atoms. In certain preferred embodiments, a 10-member R^2 group is selected from the group consisting of:


15




Where the R^2 unit is a 10-member ring system, this may be unsubstituted. Where R^2 is a substituted 10-member ring system, the substituents are preferably selected from C_1 - C_2 alkyl, especially methyl, $-C(O)Me$, $=O$ and C_1 - C_3 alkoxy especially methoxy.

20

Where the R^2 unit is a 9-member ring system, this may be fused aryl-cycloalkyl, for example:



optionally including up to 3 heteroatoms selected from S, O or N, or may be a 9-member fused aryl or heteroaryl system, optionally including up to 3 heteroatoms selected from S, O or N, preferably N. In each case, any heteroatoms present are preferably situated in the 5-member ring of the fused system. Desirably, where more than one heteroatom is present they are both the same such as, for example, a benzimidazole derivative, although heterogeneous heteroaryl systems are also included. Particularly preferred 9-membered R^2 groups include:



wherein R^4 represents hydrogen, methyl, CO_2H or CO_2Me .

Where the R^2 unit is a 9-member ring system, including those depicted above, this may be unsubstituted. Where R^2 is a substituted 9-member ring system, the one or more substituents are preferably selected from C_1 - C_2 alkyl, especially methyl; $-C(O)Me$; $=O$; C_1 - C_3 alkoxy, especially methoxy; CO_2H ; and CO_2Me .

In certain preferred embodiments:

where the linker unit Z is $-(CH_2)_n-$, n is preferably 2 or 3, more particularly 2;

where Z is $-CH=CH-(CH_2)_m-$, m is preferably 0 or 1, desirably 0 (i.e. Z is

most preferably $-CH=CH-$); and

where Z is $-(CH_2)_pNHC(O)-$, $-(CH_2)_pNHC(O)NH-$, $-(CH_2)_pNHC(O)O-$, $-(CH_2)_pSO_2NR^3-$ or $-(CH_2)_pNR^3SO_2-$, p is preferably 1.

5 It is to be understood that the present invention covers all combinations of particular and preferred groups described hereinabove.

10 Throughout the present specification and the accompanying claims the words "comprise" and "include" and variations such as "comprises", "comprising", "includes" and "including" are to be interpreted inclusively. That is, these words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows.

~~As used herein, the terms "halogen" or "halo" refer to fluorine, chlorine, bromine and iodine.~~

15 As used herein, the term "alkyl" (when used as a group or as part of a group) refers to a straight or branched hydrocarbon chain containing the specified number of carbon atoms. For example, C₁-C₃alkyl means a straight or branched hydrocarbon chain containing at least 1 and at most 3 carbon atoms. Examples of alkyl as used herein
20 include, but are not limited to; methyl (Me), ethyl (Et), n-propyl, i-propyl.


25 As used herein, the term "alkoxy" (when used as a group or as part of a group) refers to an alkyl ether radical, wherein the term "alkyl" is defined above. Examples of alkoxy as used herein include, but are not limited to; methoxy, ethoxy, n-propoxy, i-propoxy and the like.

30 As used herein, the term "biaryl" (when used as a group or as part of a group) refers to a group containing two aromatic rings which have two atoms in common. Examples of fused biaryl as used herein include, but are not limited to naphthyl and indyl. Said biaryl groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy , $-C(O)Me$, CO_2H , CO_2Me and $=O$.

35 As used herein, the term "hetero-biaryl" (when used as a group or as part of a group) refers to a biaryl group which contains one or more nitrogen, sulphur, or oxygen heteroatoms. Examples of hetero-biaryl as used herein include, but are not limited to; quinoline, isoquinoline, quinoxaline, benzimidazole, indolizine, indole and benzothiophene groups. Said hetero-biaryl groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy , $-C(O)Me$, CO_2H , CO_2Me and $=O$.

As used herein, the term "fused aryl-cycloalkyl" (when used as a group or as part of a group) refers to a group containing one aromatic ring and one alicyclic ring which have two atoms in common. Examples of fused aryl-cycloalkyl as used herein include, but are not limited to;

5



Said fused aryl-cycloalkyl groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me and =O.

10 As used herein, the term "fused heteroaryl-cycloalkyl" (when used as a group or as part of a group) refers to a fused aryl-cycloalkyl group, the aryl ring of which contains one or more nitrogen, sulphur, or oxygen heteroatoms. Said fused heteroaryl-cycloalkyl groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me and =O.

15

As used herein, the term "fused aryl-heterocycle" (when used as a group or as part of a group) refers to a fused aryl-cycloalkyl group, the alicyclic ring of which contains one or more nitrogen, sulphur, or oxygen heteroatoms. Examples of fused aryl-heterocycle as used herein include, but are not limited to; benzodioxolane, indoline. Said fused aryl-heterocycle groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me and =O.

20

As used herein, the term "fused heteroaryl-heterocyclic" (when used as a group or as part of a group) refers to a fused aryl-cycloalkyl group, which contains one or more nitrogen, sulphur, or oxygen heteroatoms either present as an atom shared between the two rings, or one or more heteroatoms being present in each ring. Said fused heteroaryl-heterocyclic groups may be optionally substituted with one or more groups selected from C₁-C₃alkyl, C₁-C₃alkoxy, -C(O)Me, CO₂H, CO₂Me and =O.

25

30 As used herein, the term "physiologically functional derivative" refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example an ester or an amide thereof, and includes any pharmaceutically acceptable salt, ester, or salt of such ester of a compound of formula (I) which, upon administration to a mammal, such as a human, is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof. It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide

35

physiologically functional derivatives thereof at any of the functional groups in the compounds, and that the compounds of formula (I) may be so modified at more than one position.

5 As used herein, the term "pharmaceutically acceptable" used in relation to an ingredient (active ingredient or excipient) which may be included in a pharmaceutical formulation for administration to a patient, refers to that ingredient being acceptable in the sense of being compatible with any other ingredients present in the pharmaceutical formulation and not being deleterious to the recipient thereof.

10

As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I), a salt thereof or a ~~physiologically functional derivative thereof~~ and a solvent. Such solvents for the purposes of the present invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water, in which case the solvate may be referred to as a hydrate of the solute in question.

15

20

It will be appreciated that, for pharmaceutical use, the "salt or solvate" referred to above will be a pharmaceutically acceptable salt or solvate. However, other salts or solvates may find use, for example, in the preparation of a compound of formula (I) or in the preparation of a pharmaceutically acceptable salt or solvate thereof.

25

30

Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, *J. Pharm. Sci.*, 1977, 66, 1-19. Suitable pharmaceutically acceptable salts include acid addition salts formed from the addition of inorganic acids or organic acids, preferably inorganic acids. Examples of suitable acid addition salts include hydrochlorides, hydrobromides, sulphates and acetates. Further representative examples of pharmaceutically acceptable salts include those formed from maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids. Suitable pharmaceutically acceptable salts also include alkali metal salts formed from the addition of alkali metal bases such as alkali metal hydroxides. An example of a suitable alkali metal salt is a sodium salt.

35

40

Compounds of formula (I) are of potential therapeutic benefit in the treatment and amelioration of the symptoms of many diseases of lipid metabolism including

dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity. As such, the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke.

Furthermore, it is also believed that the HM74 and HM74A receptors are involved in inflammation. Inflammation represents a group of vascular, cellular and neurological responses to trauma. Inflammation can be characterised as the movement of inflammatory cells such as monocytes, neutrophils and granulocytes into the tissues. This is usually associated with reduced endothelial barrier function and oedema into the tissues. Inflammation with regards to disease typically is referred to as chronic inflammation and can last up to a lifetime. Such chronic inflammation may manifest itself through disease symptoms. The aim of anti-inflammatory therapy is therefore to reduce this chronic inflammation and allow for the physiological process of healing and tissue repair to progress.

Examples of inflammatory diseases or conditions for which the compounds of the present invention may demonstrate utility include those of the joint, particularly arthritis (e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure), or the gastrointestinal tract (e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation resulting from infection, the enteropathy provoked by non-steroidal anti-inflammatory drugs), of the lung (e.g. adult respiratory distress syndrome, asthma, cystic fibrosis, or chronic obstructive pulmonary disease), of the heart (e.g. myocarditis), of nervous tissue (e.g. multiple sclerosis), of the pancreas, (e.g. inflammation associated with diabetes mellitus and complications thereof, of the kidney (e.g. glomerulonephritis), of the skin (e.g. dermatitis, psoriasis, eczema, urticaria, burn injury), of the eye (e.g. glaucoma) as well as of transplanted organs (e.g. rejection) and multi-organ diseases (e.g. systemic lupus erythematosus, sepsis) and inflammatory sequelae of viral or bacterial infections and inflammatory conditions associated with atherosclerosis and following hypoxic or ischaemic insults (with or without reperfusion), for example in the brain or in ischaemic heart disease.

In particular, the compounds of this invention are useful in the treatment and prevention of inflammation, diabetes and cardiovascular diseases or conditions including atherosclerosis, arteriosclerosis, hypertriglyceridemia, and mixed dyslipidaemia.

Nicotinic acid has a significant side effect profile, possibly because it is dosed at high level (gram quantities daily). The most common side effect is an intense cutaneous flushing. The compounds of the present invention preferably exhibit reduced side effects compared to nicotinic acid. HM74A has been identified as a high affinity receptor for nicotinic acid whilst HM74 is a lower affinity receptor. The compounds of the present invention are selective for HM74A. Thus, they show greater affinity for HM74A than for HM74.

The potential for compounds of formula (I) to activate HM74A may be demonstrated, for example, using the following enzyme and in vitro whole cell assays:

In-vitro testing

For transient transfections, HEK293T cells (HEK293 cells stably expressing the SV40 large T-antigen) were maintained in DMEM containing 10 % foetal calf serum and 2 mM glutamine. Cells were seeded in 90 mm culture dishes and grown to 60-80 % confluence (18-24 h) prior to transfection with vectors containing the relevant DNA inserts using Lipofectamine reagent. For transfection, 9 µg of DNA was mixed with 30 µl Lipofectamine in 0.6 ml of Opti-MEM (Life Technologies Inc.) and was incubated at room temperature for 30 min prior to the addition of 1.6 ml of Opti-MEM. Cells were exposed to the Lipofectamine/DNA mixture for 5 h and 6 ml of 20 % (v/v) foetal calf serum in DMEM was then added. Cells were harvested 48 h after transfection. Pertussis toxin treatment was carried out by supplementation into media at 50 ngml⁻¹ for 16 h. All transient transfection studies involved co-transfection of receptor together with the G_{i/o} G protein, G_{o1}α.

For generation of stable cell lines the above method was used to transfect CHO-K1 cells seeded in six well dishes grown to 30 % confluence. These cells were maintained in DMEM F-12 HAM media containing 10 % foetal calf serum and 2 mM glutamine. 48 h post-transfection the media was supplemented with 400 µg/ml G418 for selection of antibiotic resistant cells. Clonal CHO-K1 cell lines stably expressing HM74A were confirmed by [³⁵S]-GTPγS binding measurements, following the addition of nicotinic acid.

P2 membrane preparation - Plasma membrane-containing P2 particulate fractions were prepared from cell pastes frozen at -80°C after harvest. All procedures were carried out at 4°C. Cell pellets were resuspended in 1 ml of 10 mM Tris-HCl and 0.1 mM EDTA, pH 7.5 (buffer A) and by homogenisation for 20 s with a Ultra Turrax followed by passage (5 times) through a 25-gauge needle. Cell lysates were centrifuged at 1,000 g for 10 min in a microcentrifuge to pellet the nuclei and unbroken cells and P2 particulate fractions

were recovered by microcentrifugation at 16,000 g for 30 min. P2 particulate fractions were resuspended in buffer A and stored at -80°C until required.

5 $[^{35}\text{S}]\text{-GTP}\gamma\text{S}$ binding - assays were performed at room temperature in 96-well format as described previously (Wieland, T. and Jakobs, K.H. (1994) *Methods Enzymol.* **237**, 3-13). Briefly, membranes (10 µg per point) were diluted to 0.083 mg/ml in assay buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl₂, pH7.4) supplemented with saponin (10 mg/l) and pre-incubated with 10 µM GDP. Various concentrations of nicotinic acid or related molecules were added, followed by $[^{35}\text{S}]\text{-GTP}\gamma\text{S}$ (1170 Ci/mmol, Amersham) at 10 0.3 nM (total vol. of 100 µl) and binding was allowed to proceed at room temperature for 30 min. Non-specific binding was determined by the inclusion of 0.6 mM GTP. Wheatgerm agglutinin SPA beads (Amersham) (0.5 mg) in 25µl assay buffer were added and the whole was incubated at room temperature for 30 min with agitation. Plates were centrifuged at 1500 g for 5 min and bound $[^{35}\text{S}]\text{-GTP}\gamma\text{S}$ was determined by 15 scintillation counting on a Wallac 1450 microbeta Trilux scintillation counter.

In-vivo testing

20 HM74A agonists are tested in male Spague-Dawley rats (200-250grammes) which have been fasted for at least 12 hours prior to the study. The compounds are dosed intravenously (5ml/kg) or by oral gavage (10ml/kg). Blood samples (0.3ml tail vein bleed) are taken pre-dose and at three times post-dose (times ranging from 15minutes to 8 hours post-dose). Each blood sample is transferred to a heparin tube (Becton Dickinson Microtainer, PST LH) and centrifuged (10,000 g for 5 minutes) to produce a 25 plasma sample. The plasma samples are assayed for levels of non-esterified fatty acids (NEFA) using a commercially available kit (Randox). Inhibition of plasma NEFA levels, relative to pre-dose levels, is used as a surrogate for HM74A agonist activity.

30 Compounds according to Formula (I) have been synthesised (see synthetic examples below) and tested in one or more of the assays discussed above. All of the compounds have an EC₅₀ of 5.0 or greater and an efficacy of 30% or greater.


35 As indicated above, compounds of Formula (I) are useful in human or veterinary medicine, in particular as activators of HM74A, in the management of dyslipidaemia and hyperlipoproteinaemia.

40 Thus, there is provided as a further aspect of the present invention a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, for use in human or veterinary medicine, particularly in the treatment of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as

diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity. As such, the compounds are also provided for use in the treatment of coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke.

It will be appreciated that references herein to treatment extend to prophylaxis, prevention of recurrence and suppression of symptoms as well as the treatment of established conditions.

According to another aspect of the invention, there is provided the use of a compound of formula (Ia).



or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein

R^1 represents hydrogen, halogen or C_1 - C_3 alkyl;

R^2 represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; and $-O-$;

n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

R³ represents hydrogen or C₁-C₄alkyl,

in the manufacture of a medicament for the treatment of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia. In particular, the use is provided of a compound of Formula (Ia) in the manufacture of a medicament for the treatment of diabetic dyslipidaemia or mixed dyslipidaemia, heart failure, hypercholesterolemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease, stroke and cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.

It is to be understood that this aspect of the present invention relates with respect to the use of compounds of Formula (Ia), to all combinations of particular and preferred groups described herein above for compounds of Formula (I).

Additionally, the present invention provides the use of a compound of formula (Ia) or a physiologically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of inflammatory diseases or conditions of the joint, particularly arthritis (e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure), or of the gastrointestinal tract (e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation resulting from infection, the enteropathy provoked by non-steroidal anti-inflammatory drugs), of the lung (e.g. adult respiratory distress syndrome, asthma, cystic fibrosis, or chronic obstructive pulmonary disease), of the heart (e.g. myocarditis), of nervous tissue (e.g. multiple sclerosis), of the pancreas, (e.g. inflammation associated with diabetes mellitus and complications thereof, of the kidney (e.g. glomerulonephritis), of the skin (e.g. dermatitis, psoriasis, eczema, urticaria, burn injury), of the eye (e.g. glaucoma) as well as of transplanted organs (e.g. rejection) and multi-organ diseases (e.g. systemic lupus erythematosus, sepsis) and inflammatory sequelae of viral or bacterial infections and inflammatory conditions associated with atherosclerosis and following hypoxic or ischaemic insults (with or without reperfusion), for example in the brain or in ischaemic heart disease.

In a further or alternative aspect there is provided a method for the treatment of a human or animal subject with a condition where under-activation of the HM74A receptor contributes to the condition or where activation of the receptor will be beneficial, which method comprises administering to said human or animal subject an effective amount of a compound of formula (Ia) or a physiologically acceptable salt or solvate thereof.

Again, it is to be understood that this aspect of the present invention relates with respect to the use of compounds of Formula (Ia), to all combinations of particular and preferred groups described herein above for compounds of Formula (I).

5 More particularly, the present invention provides a method for the treatment of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic
10 dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, which method comprises administering to
15 said human or animal subject an effective amount of a compound of formula (Ia) or a physiologically acceptable salt or solvate thereof. As such, these compounds may also find favour in methods for the treatment of coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, which methods comprise
administering to said human or animal subject an effective amount of a compound of formula (Ia).

The amount of a HM74A modulator which is required to achieve the desired biological effect will, of course, depend on a number of factors, for example, the mode of
20 administration and the precise clinical condition of the recipient. In general, the daily dose will be in the range of 0.1mg - 1g/kg, typically 0.1 - 100mg/kg. An intravenous dose may, for example, be in the range of 0.01mg to 0.1g/kg, typically 0.01mg to 10mg/kg, which may conveniently be administered as an infusion of from 0.1µg to 1mg, per minute. Infusion fluids suitable for this purpose may contain, for example, from
25 0.01µg to 0.1mg, per millilitre. Unit doses may contain, for example, from 0.01µg to 1g of a HM74A modulator. Thus ampoules for injection may contain, for example, from 0.01µg to 0.1g and orally administrable unit dose formulations, such as tablets or capsules, may contain, for example, from 0.1mg to 1g. No toxicological effects are indicated/expected when a compound of the invention is administered in the above
30 mentioned dosage range.

A compound of the present invention may be employed as the compound *per se* in the treatment of a disease where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, but is preferably presented
35 with an acceptable carrier in the form of a pharmaceutical formulation. The carrier must, of course, be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the HM74A modulator as a unit-dose formulation, for example, a tablet, which may contain from 0.05% to 95% by weight
40 of the HM74A modulator.

The formulations include those suitable for oral, rectal, topical, buccal (e.g. sub-lingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration.

5

There is also provided according to the invention a process for preparation of such a pharmaceutical composition which comprises mixing the ingredients.

10

Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges or tablets, each containing a predetermined amount of a HM74A modulator; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. In general, the formulations are prepared by uniformly and intimately admixing the active HM74A modulator with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product. For example, a tablet may be prepared by compressing or moulding a powder or granules of the HM74A modulator optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s). Moulded tablets may be made by moulding, in a suitable machine, the powdered compound moistened with an inert liquid diluent.

15

20

25

30

35

40

Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline cellulose, sugar, maize-starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl *p*-hydroxybenzoates or sorbic acid. The preparations may also contain buffer salts, flavouring, colouring and/or sweetening agents (e.g. mannitol) as appropriate.

Formulations suitable for buccal (sub-lingual) administration include lozenges comprising a HM74A modulator in a flavoured base, usually sucrose and acacia or tragacanth, and pastilles comprising the HM74A modulator in an inert base such as gelatin and glycerin or sucrose and acacia.

Formulations of the present invention suitable for parenteral administration conveniently comprise sterile aqueous preparations of an HM74A modulator, preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the HM74A modulator with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions according to the invention will generally contain from 0.1 to 5% w/w of the HM74A modulator.

Thus, formulations of the present invention suitable for parenteral administration comprising a compound according to the invention may be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multi-dose containers with an added preservative. The compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or toxicity adjusting agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. The dry solid presentation may be prepared by filling a sterile powder aseptically into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.

Formulations suitable for rectal administration are preferably presented as unit-dose suppositories. These may be prepared by admixing a HM74A modulator with one or more conventional solid carriers, for example, cocoa butter or glycerides and then shaping the resulting mixture.

Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include vaseline, lanolin, polyethylene glycols, alcohols, and combinations of two or more thereof. The HM74A modulator is generally present at a concentration of from 0.1 to 15% w/w of the composition, for example, from 0.5 to 2%.

By topical administration as used herein, we include administration by insufflation and inhalation. Examples of various types of preparation for topical administration include ointments, creams, lotions, powders, pessaries, sprays, aerosols, capsules or cartridges for use in an inhaler or insufflator or drops (e.g. eye or nose drops).

5

Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents and/or solvents. Such bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil or a solvent such as a polyethylene glycol. Thickening agents which may be used include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, microcrystalline wax and beeswax.

10

Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.

15

Powders for external application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents.

20

Spray compositions may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, 1,1,1,2-tetrafluoroethane, carbon dioxide or other suitable gas.

25

Capsules and cartridges for use in an inhaler or insufflator, of for example gelatin, may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

30

The pharmaceutical compositions according to the invention may also be used in combination with other therapeutic agents, for example in combination with other classes of dyslipidaemic drugs (e.g. statins, fibrates, bile-acid binding resins or nicotinic acid).

35

The compounds of the instant invention may be used in combination with one or more other therapeutic agents for example in combination with other classes of dyslipidaemic drugs e.g. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates or bile acid binding resins or nicotinic acid. The invention thus provides, in a

40

further aspect, the use of such a combination in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial and the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof in the manufacture of a medicament for the combination therapy of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa or obesity.

When the compounds of the present invention are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above optimally together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When combined in the same formulation it will be appreciated that the two components must be stable and compatible with each other and the other components of the formulation and may be formulated for administration. When formulated separately they may be provided in any convenient formulation, conveniently in such a manner as are known for such compounds in the art.

When in combination with a second therapeutic agent active against the same disease, the dose of each component may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.


The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof together with another therapeutically active agent.

The combination referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier thereof represent a further aspect of the invention.

The compounds of the formula (I) have useful duration of action.

The compounds of formula (I) and salts and solvates thereof may be prepared by the methodology described hereinafter, constituting a further aspect of this invention.

Method A



wherein R represents $-Z-R^2$.

A process according to the invention for preparing a compound of formula (I) comprises:

- (i) formation of an amide between the amine group of anthranilic acid (2-amino-bezoic acid) and an activated acyl transfer reagent derived from a carboxylic acid;
- (ii) where desired or necessary converting a resultant free acid or base compound of formula (I) into a physiologically acceptable salt form or vice versa or converting one salt form into another physiologically acceptable salt form.


ABBREVIATIONS

THF	Tetrahydrofuran
TFA	Trifluoroacetic Acid
DMSO	Dimethylsulphoxide
HBTU	O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate

The following non-limiting examples illustrate the present invention.

Synthetic Examples

Example 1: 2-(3-Naphthalen-1-yl-propionoylamino)-benzoic acid













3-Naphthalen-1-yl-propionic acid (20 mgs, 0.1 mmol) was dissolved in acetonitrile (1 ml). HBTU (38 mgs, 0.1 mmol) was added and the mixture stirred for 30 minutes. Then, 2-amino-benzoic acid (14 mgs, 0.1 mmol) was added followed by triethylamine (0.1ml). The reaction mixture was stirred at room temperature for 20 hours before the addition of water (0.1 ml) and evaporation under reduced pressure. The title compound was isolated using preparative HPLC. δ_H (400MHz, DMSO- d_6) 2.81 (2H, t), 3.43 (2H, t), 7.16 (1H, t), 7.43 (2H, d), 7.52-7.58 (3H, m), 7.75-7.82 (1H, m), 7.92-7.98 (2H, m), 8.14 (1H, d), 8.48 (1H, d), 11.24 (1H, br.s), 13.45 (1H, br.s); m/z 318.5 $[M-H]^+$.

HPLC conditions used for the purification : 8 minute run time. Solvents: 0.1% TFA in MeCN and 0.1% TFA in water. MeCN increased from 10% to 95% linearly over 5 minutes. Held at 95% for 1 min. Decreased to 10% linearly over 30 seconds. Equilibrated at 10% for 1.5 minutes before next injection.

Examples 2 to 23 were prepared as set out in Example 1.

Example	Structure	LCMS $[M-H]^+$
2		321.21
3		312.16
4		310.27

5		319.19 [M+H ⁺]
6		325.68
7		347.33
8		321.21
9		308.37
10		398.14
11		335.10
12		348.07
13		324.12
14		335.32

15		339.29[M+H ⁺]
16		309.28[M+H ⁺]
17		319.36
18		323.15[M+H ⁺]
19		339.83
20		319.22
21		321.69
22		317.23
23		348.23

Example 2:

δ_H (400MHz, DMSO-d6) 2.00 (2H, m), 2.45 (2H, t), 2.75 (2H, t), 6.96 (1H, t), 7.05 (1H, t), 7.11-7.15 (2H, m), 7.32 (2H, d), 7.51-7.57 (2H, m), 7.96 (1H, d), 8.50 (1H, d), 10.75 (1H, br.s), 11.20 (1H, br.s); m/z 321.21 [M-H⁺].

5 Example 4:

δ_H (400MHz, DMSO-d6) 6.09 (2H, s), 6.75 (1H, d), 6.96 (1H, d), 7.16-7.22 (2H, m), 7.44 (1H, s), 7.58 (1H, t), 8.00 (1H, d), 8.61 (1H, d), 11.34 (1H, br.s), 13.35 (1H, br.s); m/z 310.27 [M-H⁺].

10 Example 5:

δ_H (400MHz, DMSO-d6) 7.08 (1H, d), 7.23 (1H, t), 7.66 (1H, t), 7.82 (1H, t), 7.94 (1H, t), 8.03 (1H, d), 8.24 (1H, d), 8.29 (1H, s), 8.31 (1H, d), 8.62 (1H, d), 8.96 (1H, s), 9.40 (1H, s), 11.45 (1H, br.s); m/z 319.19 [M+H⁺].

15 Example 6:

δ_H (400MHz, DMSO-d6) 1.88 (2H, m), 2.37 (2H, t), 2.56 (2H, t), 5.95 (2H, s), 6.66 (1H, d), 6.81 (2H, m), 7.13 (1H, t), 7.57 (1H, t), 7.96 (1H, d), 8.47 (1H, d), 11.10 (1H, s), 13.74 (1H, br.s); m/z 325.68 [M-H⁺].

20 Example 7:

δ_H (400MHz, DMSO-d6) 3.98 (2H, d), 7.60 (3H, m), 7.92-8.03 (6H, m), 8.50 (1H, s), 8.97 (1H, t); m/z 347.33 [M-H⁺].

Example 10:

25 δ_H (400MHz, DMSO-d6) 2.97 (3H, s), 4.33 (2H, s), 7.16 (1H, t), 7.60 (1H, t), 7.70 (1H, m), 7.79 (1H, t), 8.01 (1H, d), 8.34 (1H, d), 8.43 (1H, d), 8.55 (2H, t), 9.05 (1H, m); m/z 398.14 [M-H⁺].

Example 11:

30 δ_H (400MHz, DMSO-d6) 2.34 (3H, s), 2.60 (2H, t), 3.03 (2H, t), 3.62 (3H, s), 6.94 (1H, t), 7.04 (1H, t), 7.10 (1H, t), 7.32 (1H, d), 7.48 (1H, d), 7.57 (1H, t), 7.95 (1H, d), 8.50 (1H, d), 11.15 (1H, br.s), 13.41 (1H, br.s); m/z 335.10 [M-H⁺].

Example 12:

35 δ_H (400MHz, DMSO-d6) 2.59 (2H, t), 3.38 (2H, t), 3.91 (3H, s), 7.15 (1H, t), 7.35 (1H, t), 7.43 (1H, d), 7.50 (1H, t), 7.59 (1H, t), 7.85 (2H, m), 7.97 (1H, d), 8.02 (1H, d), 8.50 (1H, d), 11.20 (1H, br.s), 13.45 (1H, br.s); m/z 348.07 [M-H⁺].

Example 13:

δ_H (400MHz, DMSO-d6) 2.86 (2H, t), 3.19 (2H, t), 7.14 (1H, t), 7.36-7.44 (2H, m), 7.49 (1H, s), 7.58 (1H, t), 7.87 (1H, d), 7.97 (2H, d), 8.48 (1H, d), 11.25 (1H, br.s), 13.55 (1H, br.s); m/z 324.12 [M-H⁺].

5 Example 14:

δ_H (400MHz, DMSO-d6) 2.90 (2H, t), 4.27 (2H, t), 6.60 (1H, d), 7.15 (1H, t), 7.36-7.44 (2H, m), 7.48-7.52 (2H, m), 7.68 (1H, t), 7.95 (1H, d), 8.22 (1H, d), 8.41 (1H, d), 11.08 (1H, br.s); m/z 335.32 [M-H⁺].

10 Example 15:

δ_H (400MHz, DMSO-d6) 2.91 (2H, t), 3.79 (3H, s), 4.46 (2H, t), 6.31 (1H, d), 6.65 (1H, dd), 7.07 (1H, d), 7.15 (1H, t), 7.22 (1H, d), 7.37 (1H, d), 7.58 (1H, t), 7.94 (1H, d), 8.43 (1H, d), 11.08 (1H, br.s), 13.53 (1H, br.s); m/z 339.29 [M+H⁺].

15 Example 16:

δ_H (250MHz, DMSO-d6) 2.93 (2H, t), 4.51 (2H, t), 6.41 (1H, d), 7.01 (1H, t), 7.10-7.17 (2H, m), 7.38 (1H, d), 7.54 (3H, m), 7.94 (1H, dd), 8.40 (1H, d), 11.05 (1H, br.s), 13.52 (1H, br.s); m/z 309.28 [M+H⁺].

20 Example 18:

δ_H (400MHz, DMSO-d6) 2.21 (3H, s), 2.88 (2H, t), 4.43 (2H, t), 6.99 (1H, t), 7.12 (3H, m), 7.45 (2H, m), 7.56 (1H, t), 7.94 (1H, dd), 8.40 (1H, d), 11.19 (1H, br.s); m/z 323.15 [M+H⁺].

25 Example 19:


δ_H (400MHz, DMSO-d6) 1.13 (3H, t), 2.60 (4H, m), 2.90 (2H, t), 5.95 (2H, s), 6.68 (2H, m), 7.13 (1H, t), 7.58 (1H, t), 7.97 (1H, d), 8.48 (1H, d), 11.12 (1H, br.s); m/z 339.83 [M-H⁺].

30 Example 21:

δ_H (400MHz, DMSO-d6) 2.36 (3H, s), 2.74 (2H, t), 3.03 (2H, t), 6.89 (1H, d), 7.08 (1H, s), 7.15 (1H, t), 7.20 (1H, d), 7.31 (1H, s), 7.59 (1H, t), 7.97 (1H, d), 8.51 (1H, d), 10.61 (1H, br.s), 11.24 (1H, br.s); m/z 321.69 [M-H⁺].


35 Acid intermediates for preparation of examples 2-23 are known compounds, either commercially available or synthesised by reported procedures with the exception of:

Acid for Example 10: [Methyl-(quinoline-8-sulfonyl)-amino]-acetic acid:



[Methyl-(quinoline-8-sulfonyl)-amino]-acetic acid was prepared from commercially available (quinoline-8-sulfonylamino)-acetic acid by methylation using excess methyl iodide in DMF and subsequent hydrolysis of the methyl ester using a methanolic solution of 2N sodium hydroxide (1:1 mixture).

Acid for Example 21: 3-Isoquinolin-4-yl-propionic acid




3-Isoquinolin-4-yl-propionic acid prepared from the known compound 3-Isoquinolin-4-yl-propionic acid *tert*-butyl ester (Jonczyk *et al*, J. Chem. Res. Synop., 1998, (5), 262-3) by deprotection under standard conditions (20% TFA in DCM for 4 hours).

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation the following claims:

Claims

1. A compound of Formula (I)



5 and salts, solvates and physiologically functional derivatives thereof, wherein

R¹ represents hydrogen, halogen or C₁-C₃alkyl;

10 R² represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

15 Z represents a linker unit selected from: -(CH₂)_n-; -CH=CH-(CH₂)_m-; -(CH₂)_pNHC(O)-; -(CH₂)_pNHC(O)NH-; -(CH₂)_pNHC(O)O-; -(CH₂)_pSO₂NR³-; -(CH₂)_pNR³SO₂-; and -O-;

n represents an integer selected from 2, 3 and 4;

20 m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

25 R³ represents hydrogen or C₁-C₄alkyl, with the proviso that when R¹ is H, Z is -(CH₂)_n- and n = 2 or 3, R² is other than indol-3-yl.

2. A compound according to claim 1 wherein R¹ is hydrogen, fluorine or methyl,


3. A compound according to claim 2 wherein R¹ is hydrogen.

30 4. A compound according to any one of claims 1-3 wherein R² is a 10-member bi-cyclic ring system.

5. A compound according to claim 4 wherein R^2 is naphthyl.
6. A compound according claim 4 wherein R^2 is a 10-member ring system having either 1 or 2 heteroatoms.

5

7. A compound according to claim 6 wherein R^2 includes 1 or 2 nitrogen heteroatoms.
8. A compound according to any one of claims 4, 6 or 7 wherein R^2 is selected from the group consisting of:



10

9. A compound according claim 4 wherein R^2 is substituted with one or more groups selected from C_1 - C_2 alkyl, $-C(O)Me$, $=O$ and C_1 - C_3 alkoxy.


10. A compound according claim 9 wherein R^2 is substituted with one or more groups selected from methyl and methoxy.

15

11. A compound according claim 1 wherein R^2 is a 9-member ring system selected from the group consisting of fused aryl-cycloalkyl, fused aryl and fused heteroaryl systems, and optionally includes 1 to 3 heteroatoms selected from S, O or N.

20

12. A compound according to claim 11 wherein R^2 is selected from the group consisting of:



wherein R⁴ represents hydrogen, methyl, CO₂H or CO₂Me.

5 13. A compound according to claim 11 wherein R² is substituted with one or more groups selected from C₁-C₃alkyl -C(O)Me, =O, C₁-C₃alkoxy, CO₂H and CO₂Me.

14. A compound according to claim 13 wherein R² is substituted with C₁-C₂alkyl or C₁-C₃alkoxy.

10

13. A compound according to claim 14 wherein R² is substituted with methyl or methoxy.

14. A compound according to any preceding claim wherein Z is -(CH₂)_n- and n is an integer selected from 2, 3 or 4.


15

15. A compound according to claim 14 wherein Z is -(CH₂)_n- and n is 2.

16. A compound according to any preceding claim for use in human or veterinary medicine.

20

17. A compound of Formula (Ia)



or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein

R¹ represents hydrogen, halogen or C₁-C₃alkyl;

R² represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; and $-O-$;

n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and


R³ represents hydrogen or C₁-C₄alkyl,

for use in the treatment of disorders of lipid metabolism including dyslipidaemia and hyperlipoproteinaemia or of inflammatory diseases or conditions.

18. A compound according to claim 17 for use in the treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity,

coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke.

19. Use of a compound of Formula (Ia)



or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein

R¹ represents hydrogen, halogen or C₁-C₃alkyl;

R² represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; and $-O-$;

n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;


p represents an integer selected from 1 and 2; and

R³ represents hydrogen or C₁-C₄alkyl,

in the manufacture of a medicament for the treatment of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia or of inflammatory diseases or conditions.

20. A method for the treatment of a human or animal subject having a condition where under-activation of the HM74A receptor contributes to the condition or where activation

of the receptor will be beneficial, which method comprises administering to said human or animal subject an effective amount of a compound of Formula (Ia).



or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein

R¹ represents hydrogen, halogen or C₁-C₃alkyl;

R² represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

Z represents a linker unit selected from: -(CH₂)_n-; -CH=CH-(CH₂)_m-; -(CH₂)_pNHC(O)-; -(CH₂)_pNHC(O)NH-; -(CH₂)_pNHC(O)O-; -(CH₂)_pSO₂NR³-; -(CH₂)_pNR³SO₂-; and -O-;


n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

R³ represents hydrogen or C₁-C₄alkyl.

21. A method for the treatment of a human or animal subject having a disorder of lipid metabolism including dislipidaemia or hyperlipoproteinaemia or having an inflammatory disease or condition, which method comprises administering to said human or animal subject an effective amount of a compound of Formula (Ia)



or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein

5 R^1 represents hydrogen, halogen or C_1 - C_3 alkyl;

R^2 represents a 9 or 10-member saturated, partially saturated or unsaturated bi-cyclic ring system optionally including from 1 to 3 heteroatoms independently selected from S, O and N;

10

Z represents a linker unit selected from: $-(CH_2)_n-$; $-CH=CH-(CH_2)_m-$; $-(CH_2)_pNHC(O)-$; $-(CH_2)_pNHC(O)NH-$; $-(CH_2)_pNHC(O)O-$; $-(CH_2)_pSO_2NR^3-$; $-(CH_2)_pNR^3SO_2-$; and $-O-$;

15

n represents an integer selected from 2, 3 and 4;

m represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2; and

20

R^3 represents hydrogen or C_1 - C_4 alkyl.

22. A pharmaceutical formulation comprising a compound according to any one of claims 1-15 in admixture with one or more physiologically acceptable diluents, excipients or carriers.

25

23. A combination for administration together or separately, sequentially or simultaneously in separate or combined pharmaceutical formulations, said combination comprising a compound according to any one of claims 1-15 together with another therapeutically active agent.

30

24. A pharmaceutical formulation comprising a compound according to any one of claims 1-15, a further active ingredient selected from the group consisting of statins, fibrates, bile-acid binding resins and nicotinic acid and one or more physiologically acceptable diluents, excipients or carriers.

5

25. A method for the preparation of a compound according to any one of claims 1-15, the method comprising the steps of:

10 (i) formation of an amide between the amine group of anthranilic acid (2-amino-bezoic acid) and an activated acyl transfer reagent derived from a carboxylic acid;

(ii) where desired or necessary converting a resultant free acid or base compound of formula (I) into a physiologically acceptable salt form or vice versa or converting one salt form into another physiologically acceptable salt form.



PCT/GB2004/003516



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.